 Personalized cloning therapies are likely to be labor intensive and expensive. This has raised social justice concerns. Perhaps cloning therapies will only be a realistic option for the very rich? Some have replied to this concern by pointing out that Cloning therapies may become cheaper, less labor intensive and more widely accessible after time. Moreover, cloning may cure diseases and not only treat symptoms. Regardless of the economic cost, it remains true of course that the cloning procedure is time consuming, rendering it inappropriate for certain clinical applications where urgent intervention is required (e.g., myocardial infarction, acute liver failure or traumatic or infectious spinal cord damage). If cloning for therapy became available, its application would thus likely be restricted to chronic conditions. Wilmut (1997), who cloned Dolly, has suggested that cloning treatments could be targeted to maximize benefit: an older person with heart disease could be treated with stem cells that are not a genetic match, take drugs to suppress her immune system for the rest of her life, and live with the side-effects; a younger person might benefit from stem cells from cloned embryos that match exactly. Devolder and Savulescu (2006) have argued that objections about economic cost are most forceful against ‘cloning for self-transplantation’ than, for example, against cloning for developing cellular models of human disease. The latter will enable research into human diseases and may result in affordable therapies and cures for a variety of common diseases, such as cancer and heart disease, which afflict people all over the world. Finally, some have pointed out that it is not clear whether cloning research is necessarily more labor intensive than experiments on cells and tissues now done in animals.